Managing adults with congenital heart disease in the catheterization laboratory: State of the art

Expert Review of Cardiovascular Therapy

Volumn 8, Issue 12, 2010, Pages 1741-1752

  MacDonald, Simon T ^a   Carminati, Mario ^a   Chessa, Massimo ^a  

^a IRCCS POLICLINICO SAN DONATO   (Italy)

Author keywords

ACHD; adults with congenital heart disease; cardiac catheterization; cardiovascular; devices; grown up congenital heart disease; GUCH

Indexed keywords

ADULT; AORTA COARCTATION; AORTA VALVE STENOSIS; ARTIFICIAL EMBOLISM; CLINICAL PRACTICE; CLIP; CONGENITAL HEART DISEASE; HEART ATRIUM SEPTUM DEFECT; HEART CATHETERIZATION; HEART LEFT RIGHT SHUNT; HEART RIGHT LEFT SHUNT; HEART RIGHT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART SURGERY; HEART VALVE PROSTHESIS; HEART VENTRICLE SEPTUM DEFECT; HUMAN; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; PATENT DUCTUS ARTERIOSUS; PULMONARY ARTERY STENOSIS; PULMONARY VALVE STENOSIS; REVIEW; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

ADULT; AGING; EMBOLIZATION, THERAPEUTIC; HEART CATHETERIZATION; HEART DEFECTS, CONGENITAL; HEART DISEASES; HEART SEPTAL DEFECTS, ATRIAL; HUMANS;

EID: 78649642164     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.10.165     Document Type: Review

References (69)

1. Warnes CA, Williams RG, Bashore TM et al. ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease). Developed in collaboration with the American Society of Echocardiography Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J. Am. Coll Cardiol. 52(23), e1-e121 (2008).
2. Rosamond W, Flegal K, Friday G et al Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115(5), e69-e171 (2007).
3. Chessa M, Carrozza M, Butera G et al. The impact of interventional cardiology for the management of adults with congenital heart defects. Catheter. Cardiovasc. Interv. 67(2), 258-264 (2006). (Pubitemid 43235160)
4. Baumgartner H, Bonhoeffer P, De Groot NM et al. ESC Guidelines for the management of grown-up congenital heart disease (new version 2010): the Task Force on the Management of Grown-up Congenital Heart Disease of the European Society of Cardiology (ESC). Eur. Heart J. DOI: 10.1093/eurheartjk/ehq249 (2010) (Epub ahead of print).
5. Hoffman JI, Kaplan S. The incidence of congenital heart disease. J. Am. Coll Cardiol. 39(12), 1890-1900 (2002).
6. Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the frst 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin. Proc. 59(1), 17-20 (1984).
7. Brochu MC, Baril JF, Dore A, Juneau M, De Guise P, Mercier LA. Improvement in exercise capacity in asymptomatic and mildly symptomatic adults after atrial septal defect percutaneous closure. Circulation 106(14), 1821-1826 (2002).
8. Salehian O, Horlick E, Schwerzmann M et al. Improvements in cardiac form and function after transcatheter closure of secundum atrial septal defects. J. Am. Coll. Cardiol. 45(4), 499-504 (2005).
9. Veldtman GR, Razack V, Siu S et al. Right ventricular form and function after percutaneous atrial septal defect device closure. J. Am. Coll. Cardiol. 37(8), 2108-2113 (2001).
10. Butera G, Romagnoli E, Saliba Z, Chessa M et al. Percutaneous closure of multiple defects of the atrial septum: procedural results and long-term follow-up. Catheter. Cardiovasc. Interv. 76(1), 121-128 (2010).
11. Bruch L, Winkelmann A, Sonntag S et al. Fenestrated occluders for treatment of ASD in elderly patients with pulmonary hypertension and/or right heart failure. J. Interv. Cardiol. 21(1), 44-49 (2008).
12. Landzberg MJ. Closure of atrial septal defects in adult patients: justifcation of the 'tipping point'. J. Interv. Cardiol. 14(2), 267-269 (2001).
13. Stolt VS, Chessa M, Aubry P et al. Closure of ostium secundum atrial septum defect with the Atriasept occluder: early European experience. Catheter. Cardiovasc. Interv. 75(7), 1091-1095 (2010).
14. Kim MS, Klein AJ, Carroll JD. Transcatheter closure of intracardiac defects in adults. J. Interv. Cardiol. 20(6), 524-545 (2007).
15. Amin Z, Hijazi ZM, Bass JL, Cheatham JP, Hellenbrand WE, Kleinman CS. Erosion of Amplatzer septal occluder device after closure of secundum atrial septal defects: review of registry of complications and recommendations to minimize future risk. Catheter. Cardiovasc. Interv. 63(4), 496-502 (2004).
16. Butera G, Carminati M, Chessa M et al. Percutaneous versus surgical closure of secundum atrial septal defect: comparison of early results and complications. Am. Heart J. 151(1), 228-234 (2006).
17. Krumsdorf U, Ostermayer S, Billinger K et al. Incidence and clinical course of thrombus formation on atrial septal defect and patient foramen ovale closure devices in 1,000 consecutive patients. J. Am. Coll. Cardiol. 43(2), 302-309 (2004).
18. Chessa M, Butera G, Carminati M. Risk of thrombus formation on devices used to close transcatheter atrial septal defect and patent foramen ovale. J. Am. Coll. Cardiol. 44(8), 1712; author reply 1714-1716 (2004).
19. Murphy JG, Gersh BJ, McGoon MD et al Long-term outcome after surgical repair of isolated atrial septal defect. Follow-up at 27 to 32 years. N. Engl. J. Med. 323(24), 1645-1650 (1990).
20. Roos-Hesselink JW, Meijboom FJ, Spitaels SE et al. Excellent survival and low incidence of arrhythmias, stroke and heart failure long-term after surgical ASD closure at young age. A prospective follow-up study of 21-33 years. Eur. Heart J. 24(2), 190-197 (2003).
21. Du ZD, Hijazi ZM, Kleinman CS, Silverman NH, Larntz K. Comparison between transcatheter and surgical closure of secundum atrial septal defect in children and adults: results of a multicenter nonrandomized trial. J. Am. Coll. Cardiol. 39(11), 1836-1844 (2002).
22. Khairy P, O'Donnell CP, Landzberg MJ. Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli: a systematic review. Ann. Intern. Med. 139(9), 753-760 (2003).
23. Wilmshurst PT, Nightingale S, Walsh KP, Morrison WL. Effect on migraine of closure of cardiac right-to-left shunts to prevent recurrence of decompression illness or stroke or for haemodynamic reasons. Lancet 356(9242), 1648-1651 (2000).
24. Schwerzmann M, Wiher S, Nedeltchev K et al. Percutaneous closure of patent foramen ovale reduces the frequency of migraine attacks. Neurology 62(8), 1399-1401 (2004).
25. Dowson A, Mullen MJ, Peatfeld R et al Migraine Intervention With STARFlex Technology (MIST) trial: a prospective, multicenter, double-blind, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache. Circulation 117(11), 1397-1404 (2008).
26. Garg P, Servoss SJ, Wu JC et al. Lack of association between migraine headache and patent foramen ovale: results of a case-control study. Circulation 121(12), 1406-1412 (2010).
27. Chessa M, Colombo C, Butera G et al. Is it too early to recommend patent foramen ovale closure for all patients who suffer from migraine? A single-centre study. J. Cardiovasc. Med. (Hagerstown) 10(5), 401-405 (2009).
28. Dua JS, Carminati M, Lucente M et al. Transcatheter closure of postsurgical residual ventricular septal defects: early and mid-term results. Catheter. Cardiovasc. Interv. 75(2), 246-255 (2010).
29. Chessa M, Butera G, Negura D et al. Transcatheter closure of congenital ventricular septal defects in adult: mid-term results and complications. Int. J. Cardiol. 133(1), 70-73 (2009).
30. Chessa M, Dua JS, Carminati M. Transcatheter closure of congenital ventricular septal defects in adults mid-term results and complications: few more considerations. Int. J. Cardiol. DOI: 10.1016/j.icard.2009.05.043 (2009) (Epub ahead of print).
31. Knauth AL, Lock JE, Perry SB et al. Transcatheter device closure of congenital and postoperative residual ventricular septal defects. Circulation 110(5), 501-507 (2004).
32. Holzer R, Balzer D, Cao QL, Lock K, Hijazi ZM. Device closure of muscular ventricular septal defects using the Amplatzer muscular ventricular septal defect occluder: immediate and mid-term results of a U.S. registry. J. Am. Coll. Cardiol. 43(7), 1257-1263 (2004). (Pubitemid 38452604)
33. Carminati M, Butera G, Chessa M et al. Transcatheter closure of congenital ventricular septal defects: results of the European Registry. Eur. Heart J. 28(19), 2361-2368 (2007). (Pubitemid 47537785)
34. Kidd L, Driscoll DJ, Gersony WM et al. Second natural history study of congenital heart defects. Results of treatment of patients with ventricular septal defects. Circulation 87(2 Suppl.), I38-I51 (1993). (Pubitemid 23042117)
35. Pedra CA, Pedra SR, Chaccur P et al. Periventricular device closure of congenital muscular ventricular septal defects. Expert Rev. Cardiovasc. Ther. 8(5), 663-674 (2010).
36. Aggarwal SK, Barik R. Infective endocarditis of a patent arterial duct in an adult, with vegetations extending to the aortic and pulmonary valves. Cardiol. Young 17(5), 565-566 (2007).
37. Campbell M. Natural history of persistent ductus arteriosus. Br. Heart J. 30(1), 4-13 (1968).
38. Cagli K, Basar FN, Cagli K et al. Multisite infective endocarditis/endarteritis in a young peripartum patient with patent ductus arteriosus and rheumatic heart valve disease: a case report. Echocardiography 27(4), 466-469 (2010).
39. Pass RH, Hijazi Z, Hsu DT, Lewis V, Hellenbrand WE. Multicenter USA Amplatzer patent ductus arteriosus occlusion device trial: initial and one-year results. J. Am. Coll. Cardiol. 44(3), 513-519 (2004).
40. Lloyd TR, Fedderly R, Mendelsohn AM, Sandhu SK, Beekman RH 3rd. Transcatheter occlusion of patent ductus arteriosus with Gianturco coils. Circulation 88(4 Pt 1), 1412-1420 (1993).
41. Dua J, Chessa M, Piazza L et al. Initial experience with the new Amplatzer Duct Occluder II. J. Invasive Cardiol. 21(8), 401-405 (2009).
42. Rosenfeld HM, Landzberg MJ, Perry SB, Colan SD, Keane JF, Lock JE. Balloon aortic valvuloplasty in the young adult with congenital aortic stenosis. Am. J. Cardiol. 73(15), 1112-1117 (1994).
43. von Kodolitsch Y, Aydin MA, Koschyk DH et al. Predictors of aneurysmal formation after surgical correction of aortic coarctation. J. Am. Coll. Cardiol. 39(4), 617-624 (2002).
44. Kron IL, Flanagan TL, Rheuban KS et al. Incidence and risk of reintervention after coarctation repair. Ann. Thorac. Surg. 49(6), 920-925; discussion 925-926 (1990).
45. Campbell M. Natural history of coarctation of the aorta. Br. Heart J. 32(5), 633-640 (1970).
46. Knyshov GV, Sitar LL, Glagola MD, Atamanyuk MY. Aortic aneurysms at the site of the repair of coarctation of the aorta: a review of 48 patients. Ann. Thorac. Surg. 61(3), 935-939 (1996).
47. Suarez de Lezo J, Pan M, Romero M et al. Balloon-expandable stent repair of severe coarctation of aorta. Am. Heart J. 129(5), 1002-1008 (1995).
48. Harrison DA, McLaughlin PR, Lazzam C, Connelly M, Benson LN. Endovascular stents in the management of coarctation of the aorta in the adolescent and adult: one year follow up. Heart 85(5), 561-566 (2001).
49. Butera G, Heles M, MacDonald ST, Carminati M. Aortic coarctation complicated by wall aneurysm: The role of covered stents. Catheter. Cardiovasc. Interv. DOI: 10.1002/ccd.22756 (2010) (Epub ahead of print).
50. Butera G, Gaio G, Carminati M. Redilation of e-PTFE covered CP stents. Catheter. Cardiovasc. Interv. 72(2), 273-277 (2008).
51. Hayes CJ, Gersony WM, Driscoll DJ et al Second natural history study of congenital heart defects. Results of treatment of patients with pulmonary valvar stenosis. Circulation 87(2 Suppl.), I28-I37 (1993).
52. Earing MG, Connolly HM, Dearani JA, Ammash NM, Grogan M, Warnes CA. Long-term follow-up of patients after surgical treatment for isolated pulmonary valve stenosis. Mayo Clin. Proc. 80(7), 871-876 (2005).
53. McCrindle BW, Kan JS. Long-term results after balloon pulmonary valvuloplasty. Circulation 83(6), 1915-1922 (1991).
54. Rao PS, Thapar MK, Kutayli F. Causes of restenosis after balloon valvuloplasty for valvular pulmonary stenosis. Am. J. Cardiol. 62(13), 979-982 (1988).
55. Peng LF, McElhinney DB, Nugent AW et al. Endovascular stenting of obstructed right ventricle-to-pulmonary artery conduits: a 15-year experience. Circulation 113(22), 2598-2605 (2006).
56. Bonhoeffer P, Boudjemline Y, Saliba Z et al. Percutaneous replacement of pulmonary valve in a right-ventricle to pulmonary-artery prosthetic conduit with valve dysfunction. Lancet 356(9239), 1403-1405 (2000).
57. Coats L, Khambadkone S, Derrick G et al Physiological and clinical consequences of relief of right ventricular outfow tract obstruction late after repair of congenital heart defects. Circulation 113(17), 2037-2044 (2006).
58. Nordmeyer J, Khambadkone S, Coats L et al. Risk stratifcation, systematic classifcation, and anticipatory management strategies for stent fracture after percutaneous pulmonary valve implantation. Circulation 115(11), 1392-1397 (2007).
59. Boone RH, Webb JG, Horlick E et al. Transcatheter pulmonary valve implantation using the Edwards S API EN transcatheter heart valve. Catheter. Cardiovasc. Interv. 75(2), 286-294 (2010).
60. Schievano S, Taylor AM, Capelli C et al First-in-man implantation of a novel percutaneous valve: a new approach to medical device development. EuroIntervention 5(6), 745-750 (2010).
61. O'Laughlin MP. Catheterization treatment of stenosis and hypoplasia of pulmonary arteries. Pediatr. Cardiol. 19(1), 48-56; discussion 57-58 (1998).
62. Marini D, Boudjemline Y, Agnoletti G. Closure of extracardiac Fontan fenestration by using the covered Cheatham Platinum stent. Catheter. Cardiovasc. Interv. 69(7), 1002-1006 (2007).
63. Cowley CG, Badran S, Gaffney D, Rocchini A P, Lloyd TR. Transcatheter closure of fontan fenestrations using the Amplatzer septal occluder: initial experience and follow-up. Catheter. Cardiovasc. Interv. 51(3), 301-304 (2000).
64. Balzer DT, Johnson M, Sharkey AM, Kort H. Transcatheter occlusion of baffe leaks following atrial switch procedures for transposition of the great vessels (d-TGV). Catheter. Cardiovasc. Interv. 61(2), 259-263 (2004).
65. Hill KD, Fudge JC, Rhodes JF. Complete resolution of systemic venous baffe obstruction and baffe leak using the gore excluder(R) covered stent in two patients with transposition of the great arteries and prior mustard procedure. Catheter. Cardiovasc. Interv. DOI: 10.1002/ccd.22567 (2010) (Epub ahead of print).
66. MacLellan-Tobert SG, Cetta F, Hagler DJ. Use of intravascular stents for superior vena caval obstruction after the Mustard operation. Mayo Clin. Proc. 71(11), 1071-1076 (1996).
67. Chintala K, Forbes TJ, Karpawich PP. Effectiveness of transvenous pacemaker leads placed through intravascular stents in patients with congenital heart disease. Am. J. Cardiol. 95(3), 424-427 (2005).
68. Ruiz CE, Feldman TE, Hijazi ZM et al. Interventional fellowship in structural and congenital heart disease for adults. Catheter. Cardiovasc. Interv. 76(4), E90-E105 (2010).
69. Feldman T, Ruiz CE, Hijazi ZM. The SCAI Structural Heart Disease Council: toward addressing training, credentialing, and guidelines for structural heart disease intervention. Catheter. Cardiovasc. Interv. 76(4), E87-E89 (2010).